Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Transitional Cell CarcinomaBladder NeoplasmsKidney NeoplasmsUreter NeoplasmsBladder CancerNeoplasm, Bladder
Interventions
DRUG

vinflunine

solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration

Trial Locations (75)

Unknown

Local Institution, Beverly Hills

Local Institution, La Jolla

Local Institution, Los Angeles

Local Institution, Santa Monica

Local Institution, Stanford

Local Institution, Vallejo

Local Institution, Aurora

Local Institution, New Haven

Local Institution, Washington D.C.

Local Institution, Jacksonville

Local Institution, Miami

Local Institution, Atlanta

Local Institution, Honolulu

Local Institution, Chicago

Local Institution, Joliet

Local Institution, Urbana

Local Institution, Louisville

Local Institution, Baltimore

Local Institution, Burlington

Local Institution, Ann Arbor

Local Institution, Detroit

Local Institution, Kansas City

Local Institution, St Louis

Local Institution, Las Vegas

Local Institution, Lebanon

Local Institution, Buffalo

Local Institution, New York

Local Institution, The Bronx

Local Institution, Charlotte

Local Institution, Durham

Local Institution, Cincinnati

Local Institution, Philadelphia

Local Institution, Pittsburgh

Local Institution, Providence

Local Institution, Nashville

Local Institution, Dallas

Local Institution, Seattle

Local Institution, Milwaukee

Local Institution, Liverpool

Local Institution, Sydney

Local Institution, Taree

Local Institution, Waratah

Local Institution, Westmead

Local Institution, Adelaide

Local Institution, Linz

Local Institution, Salzburg

Local Institution, Edmonton

Local Institution, London

Local Insitution, Toronto

Local Institution, Montreal

Local Institution, Caen

Local Institution, Le Mans

Local Institution, Nice

Local Institution, Paris

Local Institution, Toulouse

Local Institution, Nea Liosia

Local Institution, Jakarta

Local Institution, Genova

Local Institution, Milan

Local Institution, Roma

Local Institution, Rome

Local Institution, Viterbo

Local Institution, Cebu City

Local Institution, Quezon

Local Institution, Quezon City

Local Institution, Singapore

Local Institution, Seoul

Local Institution, Murcia

Local Institution, Palma de Mallorca

Local Institution, Santander

Local Institution, Seville

Local Institution, Linköping

Local Institution, Uppsala

Local Institution, Aarau

Local Institution, Bangkok

Sponsors
All Listed Sponsors
collaborator

Pierre Fabre Medicament

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT00101608 - Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | Biotech Hunter | Biotech Hunter